Moderna's AI-designed personalized mRNA cancer therapy succeeds in Phase 3 trial
kimmonismus · x · 2026-08-19
Moderna and Merck's AI-assisted personalized mRNA cancer treatment has succeeded in a Phase 3 trial involving 1,137 patients.
Core Mechanism:
- Sequence patient tumors and healthy DNA, using AI to identify mutations most likely to trigger an immune response.
- Produce individualized mRNA treatments encoding up to 34 neoantigens per patient.
Clinical Data:
- Phase 2 showed 68.8% cancer-free survival at 5 years (vs. 49.1% with Keytruda alone).
- 49% lower risk of recurrence or death; 59% lower risk of distant metastasis or death.
- The larger Phase 3 trial has now confirmed these results.
More from Apps
- Benchling launches Science Foundries: agents and scientists running labs end-to-end — nlarusstone · 2026-10-16
- ChatGPT's Dot Reviewed: Your Chief of Staff Is Still Just a Codex Wrapper — infinitely_zero · 2026-10-16
- Perplexity API now available in Lovable apps for real-time cited web answers — AravSrinivas · 2026-10-16
- Nvidia NemoClaw makes TIME's Best Inventions of 2026 as an agent that can't break containment — NVIDIAAI · 2026-10-16
- Box AI Extract plus OpenAI Decisions API automates document routing — craigsdennis · 2026-10-16
- Full 49-minute walkthrough: editing Facebook ads with Opus 5.5 — alexgoughcooper · 2026-10-16